Institute of Anal-colorectal Surgery, No, 150 Central Hospital of PLA, No, 2, Huaxiaxi Road, 471000, Luoyang, China.
Diagn Pathol. 2012 Apr 20;7:45. doi: 10.1186/1746-1596-7-45.
Breast cancer is one of the most common cancers in the world, and the identification of biomarkers for the early detection of breast cancer is a relevant target. The present study aims to determine serum peptidome patterns for screening of breast cancer.
The present work focused on the serum proteomic analysis of 36 healthy volunteers and 37 breast cancer patients using a ClinProt Kit combined with mass spectrometry (MS). This approach allows the determination of peptidome patterns that are able to differentiate the studied populations. An independent group of sera (36 healthy volunteers and 37 breast cancer patients) was used to verify the diagnostic capabilities of the peptidome patterns blindly. An immunoassay method was used to determine the serum mucin 1 (CA15-3) of validation group samples.
Support Vector Machine (SVM) Algorithm was used to construct the peptidome patterns for the identification of breast cancer from the healthy volunteers. Three of the identified peaks at m/z 698, 720 and 1866 were used to construct the peptidome patterns with 91.78% accuracy. Furthermore, the peptidome patterns could differentiate the validation group achieving a sensitivity of 91.89% (34/37) and a specitivity of 91.67% (33/36) (> CA 15-3, P < 0.05).
These results suggest that the ClinProt Kit combined with MS shows great potentiality for the diagnosis of breast cancer.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1501556838687844.
乳腺癌是世界上最常见的癌症之一，寻找用于乳腺癌早期检测的生物标志物是一个相关目标。本研究旨在确定用于乳腺癌筛查的血清肽组图谱。
本研究使用 ClinProt 试剂盒结合质谱（MS）对 36 名健康志愿者和 37 名乳腺癌患者的血清进行了蛋白质组分析。这种方法可以确定能够区分研究人群的肽组图谱。使用一组独立的血清（36 名健康志愿者和 37 名乳腺癌患者）来盲法验证肽组图谱的诊断能力。使用免疫测定法来确定验证组样本的血清粘蛋白 1（CA15-3）。
支持向量机（SVM）算法用于构建从健康志愿者中识别乳腺癌的肽组图谱。在 m/z 698、720 和 1866 处鉴定出的三个峰被用于构建具有 91.78%准确性的肽组图谱。此外，肽组图谱能够区分验证组，达到 91.89%（34/37）的敏感性和 91.67%（33/36）的特异性（> CA 15-3，P<0.05）。
这些结果表明，ClinProt 试剂盒结合 MS 显示出用于诊断乳腺癌的巨大潜力。
